
    
      This study will be a phase I/II open label interventional case series. Twenty patients with
      retinal angiomatous proliferation will be randomized to receive intravitreal ranibizumab at a
      dose of 0.3mg/0.05 ml or 0.5mg/0.05 ml. Patients will receive ranibizumab via a pars plana
      injection on a monthly basis for a total duration of therapy of 12 months. Patients will be
      followed for a complete 12-month treatment course.
    
  